Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

mirogabalin

Daiichi Sankyo logo

Daiichi Sankyo starts mirogabalin trial in spinal injury pain

Trial will enrol 274 subjects with post-spinal cord injury neuropathic pain

- PMLiVE

Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3

Contender could offer potency without dose-limiting toxicities

Daiichi Sankyo logo

Daiichi gets breakthrough status for pre-NDA leukaemia drug

Quizartinib could have an advantage over rival drug Rydapt

- PMLiVE

CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

US advisors recommend GSK's shingle vaccine be used instead of Merck's rival product

- PMLiVE

GSK’s shingles vaccine Shingrix claims US approval

Becomes first alternative to Merck & Co’s Zostavax

- PMLiVE

GSK’s Shingrix sails through FDA advisory committee

Shingles vaccine data proved safe and effective, says the panel

- PMLiVE

GSK’s pipeline cull claims sirukumab, and possibly rare disease unit

Makeover designed to deliver a leaner, fitter company in 2020

Daiichi Sankyo logo

Daiichi drug hits mark in shingles pain, but misses in other indications

ALDAY trial shows mirogabalin was unable to reduce pain for fibromyalgia patients

- PMLiVE

GSK makes case for revaccination with Shingrix

The pharma giant seeks regulatory approval to treat people aged 50 plus

- PMLiVE

Kite bags $90m upfront in two Asian deals for lead CAR-T drug

Partners with Daiichi Sankyo and Fosun Pharma to focus in on non-Hodgkin lymphoma

- PMLiVE

GSK files shingles vaccine Shingrix in Europe

Blockbuster hopeful would compete with Merck & Co’s Zostavax

- PMLiVE

GSK’s blockbuster hopeful Shingrix filed in US

Clinical data showed shingles vaccine had 90% efficacy in elderly patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links